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ABSTRACT 
ANTISENSE OLIGONUCLEOTIDES: PSORALEN PHOTOREACTIVITY AND ENZYMATIC 
RESISTANCE. Steven J. Ugent and Francis P. Gasparro. Department of 
Dermatology, Yale University School of Medicine, New Haven, CT. 
Psoralen-modified antisense oligodeoxyribonucleotides previously have 
been used to prolong sequence-specific inhibition of gene expression. The 
efficacy of oligonucleotides has been limited, in part, by their 
degradation by cellular nucleases. Modifications of the 
sugar-phosphodiester backbone with methylphosphonates in order to increase 
resistance to enzymatic degradation have produced several disadvantages. 
In order to determine whether limited substitutions of methylphosphonates 
confers ezymatic resistance, three different oligonucleotides each with 
selected bases having this modification were reacted with a 
3'-exonuclease, a 5exonuclease, and a phosphohydrolase. A 
psoralen-modified oligonucleotide was also tested. In addition, the 
ability of methylphosphonated and phosphorothioated oligonucleotides to 
undergo psoralen modification was examined. It was found that selective 
methylphosphonate substitution does increase ezymatic resistance, that the 
psoralen monoadduct, itself is somewhat protective, and that psoralen 
photochemistry with either methylphosphonates or phosphorothioates is 
comparable in efficiency to that of unmodified oligonucleotides. 
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The use of psoralens as chemotherapeutic agents dates back 
thousands of years, having been used in ancient Egypt and India since 
1200-2000 B.C.E. as a remedy for vitiligo. Preparations from the 
boiled extracts of certain umbelliferous plants either were applied 
to the skin or were ingested. Patients then exposed their skin to 
the intense Egyptian or Indian sunlight. ^ That psoralens, per se, 
were photoactive agents was not known until 1938, when Kuske 
identified natural furocoumarins in plants as photosensitizers and 
isolated bergapten (5-MOP) from the oil of bergamot. ^ Modem PUVA 
(psoralens plus longwave UV radiation (320-400 nm) or UVA) 
photochemotherapy traces its origins to the isolation of 
8-methoxypsoralen (8-MOP) from Ammi majus L. in 1947 by Fahmy and 
Abu-Shady^ and the subsequent clinical use of crystalline 8-MOP and 
sunlight to treat vitiligo by El Mofty, a leading Egyptian 
dermatologist. The development of high intensity UVA radiation 
sources by Levin and Parrish in 1975 made PUVA practical for large 
scale treatment of skin disorders throughout the entire year 
Currently, PUVA is used to treat several dermatologic disorders, 
including all forms of psoriasis, early stages of cutaneous T-cell 
lymphoma (CTCL), and vitiligo.^ Another therapeutic modality 
employing 8-MOP is extracorporeal photopheresis. Unlike PUVA, this 
phototherapy, developed by Edelson et_ aJ.J does not involve 




This approach has been used successfully to treat some patients with 
CTCL. During the last two years, trials have begun to test the 
efficacy of photopheresis in the treatment of progressive systemic 
Q Q 
sclerosis, rheumatoid arthritis, and rejection in cardiac 
transplant.^ 
Experiments to study the immunological effects of PUVA have 
recently begun. Preliminary evidence indicates that PUVA is able to 
suppress skin allograft rejection in mice. Pretreatment with PUVA 
and reinfusion of photodamaged cells into the host attenuated the in 
vivo and in vitro response to alloantigen. ^ Although the precise 
mechanism of this effect has yet to be elucidated, this result along 
with the preliminary data from cardiac transplants and the successes 
with CTCL seem to indicate that PUVA and photopheresis may be 
affecting T-cells. 
PHOTOBIOLOGY OF 8-MOP 
8-MOP is a planar tricyclic aromatic compound that can 
intercalate between nucleic acid base pairs. Diagram 1 A shows the 
structure and UV absorbance spectra for 8-MOP and another psoralen 
compound, 4'-aminomethyl-b,5', 8-trimethylpsoralen (AMT). The peak 
near 300 nm is typical of psoralen regardless of the nature of the 
substituents. In the absence of UV radiation, a molecular complex 
involving non-covalent linkages is formed. Activation of the 
intercalated complex with UVA light leads to a photochemical reaction 
which results in a covalent C^-cycloaddition with the pyrimidines, 
primarily thymines, in DNA. Two types of monoadducts (see diagram 1 
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A: Structure and UV absorbance spectra of 8-MOP and AMT. 




Sage and Moustacchi have shown Chat the sequence 5'- TpApT -3' is a 
12 
preferential site for 8-MOP photoadduct formation. The 
4',5'-monoadduct can absorb a second UVA photon and undergo another 
C4-cycloaddition with a pyrimidine on another strand of DMA 
resulting in an interstrand crosslink (see diagram 1 B). 
DMA is not the only target for psoralens. Covalent addition of 
psoralens to unsaturated fatty acids1 and proteins1 as well as 
oxidation of lipids^ has been reported. Several groups have 
demonstrated that 8-MOP illuminated with UVA produces singlet oxygen 
which in turn may cause DMA damage as well as oxidation of amino 
acids>17 Which of these effects is responsible for the clinical 
efficacy of PUVA and photopheresis is not precisely known. 
OLIGONUCLEOTIDES AS INHIBITORS OF GENE EXPRESSION 
One method by which 8-MOP could be made to specifically target 
DNA is by employing antisense oligodeoxynucleotides, short segments 
of DNA that have a complementary base sequence to a particular gene. 
The use of antisense RNA and DNA both naturally and synthetically has 
proven to be a powerful means of modulating gene expression. This 
regulation was first recognized as a naturally occurring mechanism in 
prokaryotes. It has been shown that processes such as plasmid 
18 19 20 
replication, osmoregulation, transposition, and phage 
21 
reproduction all involve an interaction of a "sense” and a short 
"antisense" transcript. Several eukaryotic RNA species have been 
22 
identified containing complementary sequences to known genes. 
Although many have been isolated and shown to regulate translation in 
21 
vitro. their regulatory role, in vivo. remains undefined. 
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Control of gene expression by synthetic oligonucleotides was 
o o o / 
first demonstrated in vitro by two different groups. ’ Soon 
thereafter, in 1978, Zamecnik and Stephenson used a synthetic 
oligomer complementary to terminal repeats of Rous sarcoma virus 
(RSV) RNA to inhibit RSV replication and cell transformation in 
cultured cells. Control of cellular gene expression by antisense 
oligonucleotides to mRNA was accomplished eight years later by both 
9 f) 97 ~ 
Zamecnik et. al. and Wickstrom et_. al. These initial 
experiments have lead to the widespread use of this technique to 
inhibit gene expression. Yet, this inhibition was only transient 
because of the oligomers' susceptibility to nuclease digestion. One 
way to increase delivery of antisense oligomers to their targets is 
to integrate an antisense gene construct in the genome of a cell. 
Izant and Weintraub, in 198A, were able to suppress thymidine kinase 
expression by inserting an artificial antisense gene in the herpes 
98 
simplex virus. Since then, numerous artificial antisense genes 
have been described, with plants being the first multicellular 
eukaryotic organism in which this artificial regulation was 
29 
reported. 
Although this is a powerful tool for elucidating the function of 
various genes and gene products, a simpler, more direct, and more 
applicable approach for higher eukaryotes is the use of extrinsic 
oligodeoxynucleotides, which can be prepared by automated chemical 
synthesis. Ideally, the oligomer must be able to reach its target, 
remain intact, bind selectively, and retain its effects over a long 
period of time. 
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UPTAKE OF OLIGONUCLEOTIDES 
Two groups have shown that oligomers are actively transported 
30 31 across the plasma membrane via an endocytic process. ’ One of 
the groups, Loke et_. al. . suggested that this transport may involve 
30 the binding of the oligomer to a plasma membrane protein. Using 
oligo(dT)-cellulose beads, they were able to affinity purify an 
80-kDa protein that may be associated with cellular uptake of the 
oligos. They also showed that this uptake is temperature dependent 
and is saturable. Yakubov e_t. al. demonstrated that undegraded 
oligonucleotides may be found in cellular cytoplasm and nuclei. 
Recently, it has been shown that an antisense oligonucleotide 
phosphorothioate (see diagram 2) specific for the rev gene-encoded 
RNA of HIV-1 is concentrated in the nucleus and achieves a steady 
state concentration within 0.5 to 5 hours depending on the cell 
line. This is especially important if the target of the 
antisense is not RNA, on which most of the antisense work focuses, 
but the genomic DNA, itself. Consideration of this endocytic 
mechanism and the role of the oligomer binding protein may allow the 
construction of oligomers that more efficiently reach their targets. 
This was the rationale behind the work of Leonetti et. al. who 
attached poly(L-lysine), a polycationic drug carrier, to an 
33 oligonucleotide to enhance its uptake by endocytosis. In their 
experiments, antisense oligomers to a particular mRNA of the 
vesicular stomatitis virus (VSV) exhibited antiviral properties at 




Even if the oligomer can get into the cytoplasm or into the 
nucleus, its susceptibility to nucleases may prevent it from reaching 
its target intact in sufficient concentrations. Because of their 
greater stability, oligodeoxynucleotides, as opposed to 
oligoribonucleotides, have been used. Yet, 
oligodeoxynucleotides, themselves, are sensitive to nuclease 
digestion. Several laboratories thus have developed oligomers with 
modifications of the sugar-phosphodiester backbone. Much of the 
early work on oligonucleotide analogs was performed by Miller et. 
al., who characterized antisense compounds modified with ethyl 
35 
phophotriester or methyl phosphorate linkages (see diagram 2). 
These constructs have increased hydrophobicity and lowered water 
solubility because they lack ionizable groups and are uncharged. 
O f. 
Tidd and WareniusJ tested an N-ras antisense sequence with 
terminal methylphosphonate diester linkages for their ability to 
resist enzymatic degradation. They found that an 18-mer with two 
methylphosphonate diester linkages at the 3'-terminus was relatively 
resistant to enzymes found in fetal calf serum. These modified 
oligomers, however, have several drawbacks. Methylphosphonates have 
O / 
low solubility in aqueous media. In addition, phosphorus atoms 
with four different substitutes exhibit diastereoisomerism. Since 
the synthesis of methylphosphonates is not stereospecific, an oligo 
of length n has stereoisomers, some of which may have poor 
affinity for the target sequence. Higher concentrations are also 
required to achieve inhibition. Presumedly, this is because unlike 
unmodified oligos, methylphosphonates do not function by causing 
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Structure of normal and modified oligonucleotides. I, 
normal phosphate linkage; II, ethyl phosphotriester; III, a 




RNase H catalyzed cleavage of mRNA but by physically blocking 
ribosome binding during protein synthesis. 
Another analogue that has been extensively studied is the 
phosphorothioate oligonucleotide, in which one of the nonbridging 
oxygen atoms is replaced by a sulfur atom (see diagram 2). This 
oligomer has good water solubility, unlike the methylphosphonates. 
3 7 
It is also protected against nucleases, and has been shown to be 
stable for several hours (between 7 and 19 hours depending on the 
particular cellular system) in adult human serum, rat cerebrospinal 
fluid, RPMI with 10% fetal bovine serum, undiluted fetal bovine 
38 39 
serum, and HeLa cell extract. Matsukura et. al. synthesized 
oligonucleotides complementary to regions of the rev (art/trs) gene 
of HIV-1 that are essential for efficient viral replication. These 
antisense oligos showed potent antiviral activity; yet, the control 
phosphorothioate oligomers which were not sequence specific also 
exhibited equally potent antiviral properties. In fact, the best 
inhibition for de novo infection was obtained with a homo-oligomer, 
S-dC2g• Ho effect, however, was observed when the homo-oligomer 
was applied to chronically affected cells. Phosphorothioates have 
been shown to inhibit reverse transcriptase in vitroand thus 
this may be one explanation of this non-specific effect in this 
system. This group has more recently demonstrated that there is 
sequence-specific antiviral activity associated with the 
phosphorothioates. ^ Antisense oligos complementary to rev mRNA 
caused a translational arrest, as measured by Northern blots, whereas 
control sequences had no such effects. In addition, as mentioned 
earlier, these oligomers preferentially target the nucleus, and 
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therefore may affect translation and transcription at a different 
stage than other oligomer analogs. 
A third class of oligomer that is resistant to nucleases is the 
a-analogs, in which the naturally occurring (3 linkage formed 
by the deoxyribose moiety with the purine or pyrimidine base is 
replaced by an a-linkage. As compared to f) oligomers, they 
bind more strongly to ribonucleotides rather than 
deoxyribonucleotides and are much more resistant to enzymatic 
degradation. z Another advantage is that the synthesis of these 
/ 9 
a-analogs yields only a single stereoisomer. An 
a-18-mer complementary to VSV mRNA coding for the nucleocapsid 
protein, however, did not inhibit in vitro translation . ^ This 
result was ascribed to the failure to induce degradation of the 
target RNA because the a-oligo - RNA complex did not activate 
RNase H. 
SPECIFICITY 
Oligomers specifically bind to complementary sequences of DNA or 
RNA through hydrogen bonding. Statistically, a sequence of 12 
nucleotides should be found only once in the E. coli genome. Yet, in 
human cells where the (A+T)/(G+C) ratio is 0.6, the minimum length 
should range from 15 (if there are only G's and C's in the 
oligonucleotide) to 19 (if there are only A's and T's) when a DNA 
sequence is the target 
45 
When mRNA is the target, assuming that 
about 0.5% of the genome is transcribed into mRNA, the minimum length 
for uniqueness should be 11 to 15. The actual calculation depends on 
the sequence, especially for (G+C)-rich oligonucleotides, because one 
10 

dinucleotide sequence, CpG, is under-represented in eukaryotic 
genomes as compared to a random distribution. ^ The evaluation of 
specificity must also take into account the formation of stable 
''mismatched” non-Watson-Crick base pairs, especially G-T. This 
could lead to an increase of non-specific binding. It also has been 
shown statistically that increasing the length of the oligonucleotide 
beyond 25 bases confers no additional specificity to it. At this 
length, a single mismatch would represent only a small percentage of 
the total oligonucleotide and thus would be "tolerated" quite well. 
CONJUGATED OLIGONUCLEOTIDES 
In order to increase the affinity of the oligomers for their 
target sequence and prolong their inhibitory effects, several groups 
have covalently linked the oligomers to intercalating agents. 
Intercalating agents are polycyclic aromatic compounds which insert 
their planar aromatic ring between two consecutive base pairs of 
double-stranded DNA. They increase the affinity of the oligo by 
providing additional binding energy which stabilizes the complex. 
Asseline e_t. al.^ constructed oligos with a acridine covalently 
linked to the 3' terminus. Subsequently, oligos with an attached 
acridine derivative were reported to specifically inhibit translation 
of mRNA for phage TA^ and of rabbit f3-globin4’^ more 
efficiently than unmodified oligos. In order to increase the 
affinity and the stability of the oligomers, Thuong e_t. aT. z 
linked an acridine derivative to an a-oligo. In addition, a 
number of reagents have been linked to oligos to induce irreversible 





covalently attached an alkylating group to 3' terminus. 
EDTA has also been conjugated to antisense oligos. This modification 
can give rise to reactive oxygen-containing radicals in the vicinity 
of the DNA; however, Boutorin et. reported that there was 
some nonspecificity and autodegradation with time. Other metal 
57 
complexes that have been used include o-phenantroline-Cu(I) and 
porphyrin-Fe(II). 
PHOTOACTIVE INTERCALATING AGENTS 
The synthesis of oligomers containing a photoinducible 
cross linking group was originated to overcome some of the above 
mentioned problems with oligos in vivo. Ts'o and Miller et. al. 
reasoned that methylphosphonated oligos could be more effective if 
53 
they could bind covalently to their target. To this end, they 
linked a psoralen molecule (AMT) to an oligodeoxyribonucleoside via 
an amino-alkyl tether. Lee et. al. in the same laboratory were able 
to demonstrate that these psoralen-modified oligomers were able to 
crosslink single-stranded DNA in vitro in the presence of UVA 
Using a different psoralen derivative, 4,5',8-trimethylpsoralen, 
Pieles and Englisch showed that the intercalated psoralen group 
contributed to the stability of the duplex formed between the 
psoralen-modified oligodeoxyribonucleotide and a synthetic 
21-mer. They reported that the Tm of this complex increased by 
about 8°C. In addition, their group confirmed that a 
psoralen-modified antisense oligo can specifically bind and 
"crosslink" single-stranded DNA in vitro. Kean et. al.^ used the 
psoralen-derivatized oligonucleoside methylphosphonates mentioned 
12 

above to target rabbit glob in mRNA in vitro. Crosslinking was 
detected in the single-stranded regions of the mRNA. Further work by 
Lee et_. al. suggested that in vitro this psoralen-modified oligo 
did not crosslink double-stranded DNA. Even when the duplex was in 
an open form during transcription, it was not accessible to oligomer 
binding. Other photocross linking agents that have been tethered to 
58 58 
oligonucleotides include azidophenacyl, proflavine, and 
59 
porphyrins. 
DNA AS A TARGET 
Synthetic oligonucleotides and oligonucleosides have been used to 
inhibit DNA replication, retroviral replication, pre-mRNA processing 
and protein synthesis. The target of these oligos is mRNA. Very 
little work has been done on the use of antisense directed against 
DNA. One approach to specifically target DNA has involved the 
formation of a triple helix. A homopyrimidine oligonucleotide with 
EDTA-Fe attached at a single position bound the corresponding 
homopyrimidine-homopurine tracts within double-standed DNA by triple 
helix formation and cleaved the DNA at that sight.The oligo 
was shown to be bound by Hoogsteen hydrogen bonds in the major 
groove. Unfortunately, this recognition has only been possible with 
homopyrimidine-homopurine tracts. This technique, therefore, does 
not have the same specificity as oligos that are directed to the 
linear DNA or RNA sequence. 
Recently, Gasparro et_. al. have synthesized antisense oligos 
containing psoralen monoadducts. ^ This strategy avoids using the 
chemically reactive site on the psoralen for the attachment of the 
13 

hydrocarbon tether, as is the case in the experiments described 
above. In a series of experiments, they targeted the 
/3-lactamase gene in £\_ coli and caused otherwise resistant 
strains to be susceptible to ampicillin. An effect was seen at a 
concentration about 100 times lower than would be needed to target 
mRNA. This is the first report of antisense being directed against 
DNA in cells in culture. 
Described in this paper is a series of experiments designed to 
test the susceptibility of modified oligonucleotides to enzymatic 
degradation. Previous work cited above tested oligos where every 
base was modified with a methylphosphonate. Here, only selected 
bases have the methylphosphonate substitution. Several combinations 
of the substitutions are compared to each other. Gasparro et. al. 
synthesized a 9-mer complementary to a sequence within the initiation 
region of the ft-lactamase gene of E. coli. It is this sequence 
that is used for these experiments. Modified and unmodified oligos 
containing psoralen monoadducts were synthesized and also analyzed 
for resistance to enzymatic degradation. Finally, the synthesis and 
purification of phosphorothioate oligos containing psoralen 
monoadducts is described. 
14 

MATERIALS AND METHODS 
OLIGONUCLEOTIDES 
A 9-mer (5'-GAGTATGAG-3') was synthesized on a multicolumn solid 
phase synthesizer (Applied Biosystems, Foster City, CA). 9-mers with 
methylphosphonates on the middle three bases, TAT, (9-mer-TAT), on 
the second, third, eighth, and ninth bases (9-mer-AG), and on every 
other base- the second, fourth, sixth and eighth bases- (9-mer-alt) 
were also synthesized by the same method (see table 1). These oligos 
were 5'-end labelled using T4 kinase (Boehringer-Mannheim, 
Indianapolis, IN) and [ P]-y-ATP (Amersham, Arlington Heights, 
fa"? 
IL) according to the procedure of Maniatis, et. al. Salts and 
enzymes were removed prior to the reactions using Nensorb ion 
exchange columns (Dupont, Wilmington, DE). A 15-mer 
phosphorothioated oligo antisense to part of a sequence encoding for 
ICAM-1 in human keratinocytes was purchased from Synthecell 
(Gaithersburg, MD). 
DIGESTION WITH T4 POLYMERASE 
To test for 3' exonuclease sensitivity the oligonucleotides (100 
pg/mL) were dissolved in 67 mM Tris HC1, 6.7 mM MgCl2> 16.7 mM 
(NH^)2S0^ and 10 mM fi-mercaptoethanol (pH 8.8). TA 
polymerase (Boehringer-Mannheim, Indianapolis, IN) was added (3.3 
units/gg oligo) and incubated at room temperature. The 
polymerase was inactivated at 0 time, 1 min., and 10 min. after the 
start of the reaction with 0.5 M EDTA and by heating the reaction 
15 
A 
TABLE 1: OLIGONUCLEOTIDES USED 
Abbreviation Sequence Description 
9-mer pGpApGpTpApTpGpApG unmodified 9-mer 
9-mer-alt pGmApGmTpAmTpGmApG 9-mer with every other base 
a methylphosphonate 
9-mer-TAT pGpApGmTmAmTpGpApG 9-mer with the three middle 
bases methylphosphonated 
9-mer-AG pGmAmGpTpApTpGmAmG 9-mer with second, third, 
eighth, and ninth bases 
methylphosphonated 
9-mer-MA pGpApGpT*pApTpGpApG monoadducted 9-mer 
5-mer pCpApTpApC complementary strand to 





9-mer-comp pGpGpCpApTpApGpApG complementary strand to 
middle 9 bases of 15-mer 
15-mer-MA sGsGsTsCsTsCsT* sAsT 
sGsCsCsCsAsA 
monoadducted 15-mer 
location of 4',5'-monoadduct 
16 

mixture to 75°C for 3 min. Each of the above 5'-end labelled oligos 
were tested in this manner. 
DIGESTION WITH ACID PHOSPHATASE 
To test for phosphohydrolase sensitivities, the oligonucleotides 
(200 pg/mL) were dissolved in 10 mM Na acetate (pH 5.0). Acid 
phosphatase (Sigma, St. Louis, MO) was added (0.12 units/pg 
oligo) and incubated at 37°C. The phosphatase was inactivated at 0 
time, 1 min., 10 min., and 30 min. after the start of the reaction 
with 1 M Na phosphate (pH 6.8) and by heating to 80°C for 3 min. 
DIGESTION WITH PHOSPHODIESTERASE II 
Because DNA is resistant to phosphodiesterase II degradation if a 
5' terminal phosphate exists, prior treatment with acid phosphatase, 
which removes this phosphate, was necessary. In order to follow the 
reaction, the oligos were 3'- end labelled, as the 5' label will be 
cleaved by the acid phosphatase. This labelling used terminal 
deoxynucleotidyl transferase (IBI, New Haven, CT) and 
32 
[ P]-a-CTP (Amersham, Arlington Heights, IL) according to the 
6? 
procedure by Maniatis et. ai. Acid phosphatase (0.12 
units/pg oligo) was allowed to react with the oligos for 20 min. 
The reaction was stopped as described above. Phosphodiesterase II 
(Sigma, St. Louis, MO) in 125 mM succinate HC1 (pH 6.5) was added 
(0.01 units/pg oligo and 0.001 units/oligo). This enzyme was 
stopped at 0 time, 1 min., 10 min., and 30 min. by heating to 75°C 




Results of the above reactions were analyzed using 20% 
polyacrylamide gels under denaturing conditions (8.3 M urea in 
Tris-borate-EDTA). Autoradiograms were taken using diagnostic XR 
film (Kodak, Rochester, NY). 
PHOTOCHEMISTRY WITH METHYLPHOSPHONATES 
The psoralen monoadducts of the 9-mer, 9-mer-TAI, 9-mer-alt, and 
9-mer-AG were prepared. Equimolar amounts (40 pM) of the 9-mer 
and a 5-mer (5'CAIAC-3 ') complementary to the middle five bases of 
the 9-mer were prepared in irradiation buffer (10 mM Tris, 1 mM EDTA, 
0.5 M NaCl, pH 7.8). The minihelix formed between these two 
oligomers provided intercalation sites for the psoralen (AMT or 
8- MOP, 80 pM). The chilled solution (4°C) were exposed to 400 nm 
light emanating from a monochromator (Photon Technologies 
International Inc., Princeton, NJ). Samples were withdrawn from the 
photoreaction chamber at 0 time, 1 hour, and 3 hours and then 
analyzed on gel electrophoresis as described above. 
PHOTOCHEMISTRY WITH PHOSPHOROTHIOATES 
The psoralen monoadduct of the 15-mer phosphorothioated oligo was 
also prepared. Equimolar amounts (80 pM) of the 15-mer and a 
9- mer complementary to its middle 9 bases were prepared in 
irradiation buffer (composition described above). 8-methoxypsoralen 
(8-MOP) was added to yield a final concentration of 640 pM. The 
chilled solution (4°C) was exposed to 400 nm light as described above 
for a total of 4 hours. 
18 

PURIFICATION OF 9-HER MONOADDUCT 
The 9-mer monoadduct was purified on HPLC. Reversed phase HPLC 
facilitated the separation and purification of psoralen-modified 
oligos because volatile organic solvents (acetonitrile) and salts 
(triethylammonium acetate) were used. 50 ul aliquots were applied to 
a C8 column (Vydac, Hesperia, CA). A mobile phase consisting of 
acetonitrile and 0.1 M triethyl ammonium acetate (TEA) was used with 
the following gradient to elute the oligonucleotides: 0 min: 2.5% 
TEA; 2.5 min: 2.5% TEA; 22.5 min: 12.5% TEA; 27.5 min: 12.5% TEA; 35 
min: 25% TEA; 35 min: 50% TEA; AO min: 50% TEA; 45 min: 50% TEA. A 
scanning detector (Spectra-Physics, San Jose, CA) was used to 
determine the ultraviolet absorption spectra of the eluting 
compounds. Absorbance data monitored from 200-370 nm was accumulated 
by a direct memory access board (IBM AT). Fractions were collected 
off the column and concentrated by lyophilization (Savant, 
Farmingdale, NY). Purity was confirmed on gel electrophoresis. 
PURIFICATION OF 15-MER MONOADDUCT 
The 15-mer phosphorothioated monoadduct was also purified on 
reversed phase HPLC. 500 ul aliquots were applied to a CA column as 
above with the mobile phase being acetonitrile and TEA. The 
following gradient was used to elute the oligonucleotides from the 
column: 0 min: 12.5% TEA; 5 min: 12.5% TEA; 30 min: 20% TEA; 35 min: 
20% TEA; AO min: 25% TEA; 50 min: 25% TEA. Fractions were collected, 
pooled, and concentrated as above. Purity was checked by applying a 
small portion of the concentrated sample on a C8 column (Regus, 
Morton, IL) and by running gel electrophoresis. 
19 

DIGESTION OF THE 9-HER MONOADDUCT 
A psoralen modified oligonucleotide (9-mer-MA) was also tested 
for its sensitivity to TA polymerase. TA polymerase (15 units/pg 
oligo) was added to 9-mer-MA (30 pg/mL) purified by HPLC. The 
reaction proceeded as described above and was stopped at 0, 1, 3, 10, 
and 30 min. The results were analyzed by gel electrophoresis as 
described above. 
FATE OF 9-HER IN VIVO 
The stability of the oligonucleotides when incorporated into 
cells was determined by adding the 9-mer and 9-mer-MA to E. Coli 
(XLl-Blue cells). AO uL aliquots of competent XLl-Blue cells were 
exposed to either 9-mer or 9-mer-MA at a 2.5:1 oligo:plasmid ratio. 
The oligos were introduced into the bacteria by the following heat 
shock method. After a 30 min. incubation on ice, the cells were 
placed in a A2°C water bath for A5 sec. The cells were then placed 
on ice for 2 min. and then incubated at 37°C with shaking for 1 
hour. Aliquots were taken at 0, 10 20, and 30 min. during the 
initial 30 min. incubation as well as following the A2°C heat shock 
and the one hour incubation at 37°C. Cells and media were separated 
by centrifugation, the oligonucleotides were isolated from these 
fractions, and then the oligos were analyzed on polyacrylamide gels. 




DIGESTION WITH T4 POLYMERASE 
Denaturing polyacrylamide gel electrophoresis was used to analyze 
the results of the enzymatic degradation experiments. Figure 1 shows 
the results of the reactions of the 9-mer and the three 
methylphosphonated 9-mers with TU polymerase. Lanes 4-6 correspond 
to the unmodified 9-mer at 0, 1 min., and 10 min. after the start of 
the ezymatic reaction. The single band corresponding the 9-mer in 
lane 4 is completely degraded in one minute to at least three shorter 
oligonucleotides. After 10 min., only a single band (lane 6) 
corresponding to an oligo about 3 bases long remains. 
The results of the same experiment using 9-mer-alt can be seen in 
lanes 1-3. In lane 1, the starting material is shown to be far from 
pure with evidence of 8-mer, 7-mer, 6-mer, and 5-mer contamination. 
Yet, at 1 and 10 min. the band corresponding to the 9-mer (the top 
band) is decreased in intensity and another band (about 3 bases long) 
not present in the original material has appeared. Although some 
degradation has taken place, the 9-mer-alt has not been completely 
degraded as was the unmodified 9-mer. 
Lanes 7-9 show the results of the experiment with 9-mer-TAT. The 
starting material in lane 7 is fairly pure. After 1 min. of 
digestion, the band pattern appears virtually identical to the 
starting material. Even at 10 min., only a faint increase in the 
intensity of the bands corresponding to smaller oligos can be 
detected. Similar results were observed for 9-mer-AG. In lanes 
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10-12, it can be seen that the oligomer at 0 time is essentially 
identical to the oligomer at 1 min. and 10 min. These two 
methylphosphonated oligos appear to be more resistant to T4 
polymerase than the unmodified 9-mer or the 9-mer-alt. 
DIGESTION WITH ACID PHOSPHATASE 
Figure 2 shows the reaction of unmodified 9-mer with acid 
phosphatase. Lane 1 corresponds to the starting material. Three 
different concentrations of acid phosphatase, 0.0012, 0.012, 0.12 
units/pg oligo, were used, and the reaction was stopped at 1, 3, 
10, and 30 min. An effect was seen only at the highest 
concentration. Since the acid phosphatase removes the 5'-terminal 
phosphate and the oligo is 5'-end labeled, it is the disappearance 
and the decrease in intensity of the bands that is observed. Lanes 
10-13, corresponding to the concentration of 0.12 units/pg oligo 
and the four time periods mentioned above, reveal this decrease in 
intensity. By 30 min. (lane 13) the original band has virtually 
disappeared. 
Figure 3 shows the results of the reaction using this highest 
concentration of acid phosphatase with the three methylphosphonated 
oligos. Each oligo is shown at 0, 1, 10, and 30 min. Lanes 2-4, 
detailing the reaction with 9-mer-AG, reveal the susceptibility of 
this oligo to acid phosphatase. By 10 min. (lane 3), the band is 
decreased in intensity and by 30 min. (lane A), the band has 
disappeared. The results are similar for the experiment with 
9-mer-alt (lanes 9-12). At 30 min. the band has disappeared. 
9-mer-TAT (lanes 5-8), however, appears to be more resistant to the 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Polyacrylamide gel analysis of the digestion of the 9-mer, 
9-mer-MA, and the three methylphosphonated oligonucleotides 
with T9 polymerase Lanes 1-3: 9-mer-alt at 0, 1 , and 10 
min. of i digestion. Lanes 9-6: 9-mer at 0, 1; , and 10 min. of 
digestion Lanes 7-9: 9-mer-TAT at 0, 1 , and 10 min. of 
digestion Lanes 10-12. 9-mer-AG at 0, 1 , and 10 min. of 





1 2 3 4 5 10 11 12 13 6 7 8 9 
Digestion of 9-mer with acid phosphatase. Lane 1: starting 
material. Lanes 2-5, 6-9, and 10-13: digestion times of 1, 
3, 10 and 30 min. for acid phosphatase concentrations of 





acid phosphatase. Although it is decreased in intensity, the band 
corresponding to 30 min. of reaction time (lane 8) is still visible. 
DIGESTION WITH PHOSPHODIESTERASE II 
Phosphodiesterase II requires a 5'-hydroxyl terminus in its 
substrate in order to be active. Thus, oligonucleotides, which have 
a 5' phosphate group, are resistant to this enzyme. This is shown in 
figure 4. No digestion is detected at any of the concentrations or 
reaction times tested. 
Acid phosphatase, as shown above, cleaves the 5'-phosphate group, 
exposing the 5'-hydroxyl terminus. Figure 5 shows the results of 
pre-treating the oligos with acid phosphatase and then exposing them 
to the phosphodiesterase Because the acid phosphatase cleaves the 
5'-phosphate group, the oligos were 3'-end labeled so that results 
could be followed on gel electrophoresis. Lane 1 corresponds to 
unmodified 9-mer before the 20 min. reaction with acid phosphatase 
(0.20 units/pg oligo). Lanes 2-4 reveal the results of adding 
0.001 units/pg oligo of phosphodiesterase with reaction times of 
1 min., 10 min., and 30 min, respectively. Lanes 5-7 correspond to 
the same time points with ten times the amount of enzyme (0.01 
units/pg oligo). It can be seen that the unmodified oligo is 
quite susceptible to the phosphodiesterase. As the reaction time is 
lengthened and the enzyme concentration increased, the original band 
decreases in intensity and numerous bands representing smaller oligos 
appear. After 30 min. at the higher concentration of enzyme, only a 




12 3 4 5 6 7 8 9 10 11 12 
Digestion of methylphosphonated oligonucleotides with acid 
phosphatase. Each oligonucleotide is shown at 0, 1 min., 10 
min., and 30 min. of digestion with acid phosphatase (0.12 
units/gg oligonucleotide). Lanes 1-4: 9-mer-AG. Lanes 




1 2 3 4 5 6 7 8 9 10 111213 
Digestion of 9-mer with phosphodiesterase 
starting material. Lanes 2-5, 6-9, and 10 
times of 30 sec., 3 min., 10 min., and 
phosphodiesterase concentrations of 0.001, 
units/gg oligonucleotide, respectively. 
II. Lane 1: 
13 : digestion 
30 min. for 




This same reaction was performed with the methylphosphonated 
oligonucleotides. In figure 6, lanes 1-5, 6-10, and 11-15 reveal the 
results of the reactions with 9-mer-alt, 9-mer-TAT, and 9-mer-AG, 
respectively. Unlike the unmodified oligos, the smaller fragments of 
the methylphosphonated oligos actually run slower on the gel than the 
larger fragments. This is because when the charge to mass ratio of 
the oligo is constant, the distance oligos migrate on a gel is 
proportional to their mass. This ratio, however, is not constant for 
the methylphosphonated oligos because while the phosphate groups are 
negatively charged, the methylphosphonated groups are not. A more 
negatively charged species will tend to migrate further than a less 
negatively charged one of equal mass. Thus, for example, the 
9-mer-TAT has six negatively charged groups out of its nine bases 
(charge to mass ratio - -0.67 - assuming for the example that a base 
has mass of one) while this oligo with its 5' base cleaved has 5 
charged groups out of eight bases (charge to mass ratio = -0.63). 
Thus, although the 8-mer has less mass than the 9-mer, it is also has 
less charge density. It is this latter force that predominates in 
this case. 
As above, two concentrations of the phosphodiesterase were 
tested, although at the higher concentration only a 10 min. time 
point was examined. The results show that the 9-mer-AG (lanes 11-15) 
is resistant to this enzymatic degradation; whereas, the 9-mer-alt 
and 9-mer-TAT are both degraded. It appears that the reaction 
removes one base from the 9-mer-alt and about three bases from the 
9-mer-TAT. After 30 min., the bands representing the original 
material for these two oligos have almost completely disappeared. 
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12 3 4 5 6 7 
* 
Digestion with acid phosphatase and phosphodiesterase II. 
Lane 1: 9-mer. 9-mer was treated with acid phosphatase (0.2 
units/gg oligonucleotide) and then digested with 
phosphodiesterase. Lanes 2-4: 0.001 units/gg 
oligonucleotide phosphodiesterase at 1, 10, and 30 min. of 
digestion. Lanes 5-7: 0.01 units/gg oligonucleotide at 




1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
♦ 
Digestion of methylphosphonates with acid phosphatase and 
phosphodiesterase II. As in figure 5, oligonucleotides were 
pretreated with acid phosphatase. Each oligo is shown 
before reaction with acid phosphatase, at 1, 10 and 30 min. 
following addition of phosphodiesterase (0.001 units/gg 
oligo), and 10 min. following addition of phosphodiesterase 
(0.01 units /gg oligo). Lanes 1-5: 9-mer-alt. Lanes 




PREPARATION OF 9-HER MONOADDUCT 
The monoadduct of the unmodified 9-mer was prepared with AMT. A 
representative autoradiograph of the gel used to analyze the reaction 
mixture is shown in figure 7. The reaction between the 9-mer:5-mer 
minidouble helix complex and AMT following exposure to 400 nm 
radiation for 4 hours is shown. The primary photoreaction was the 
formation of 9-mer-monoadducts (labeled MA 1 and 2). Earlier studies 
showed that MA-1 and MA-2 correspond to two forms of the 
4',5'-monoadduct (G. Miolo, unpublished results). The 5-mer 
photoproduct (ma) also was formed. 
Each of the methylphosphonated oligos were tested to see if this 
modification would interfere with the photochemistry. Figure 8 shows 
the results of the photoreactions at time 0, 1 hour, and 3 hours of 
9-mer-TAT, 9-mer-AG, and 9-mer-alt, respectively. As with the 
unmodified 9-mer, the principal reaction is formation of 9-mer 
monoadducts (labeled MA). Thus, this shows that it is possible to 
create monoadducts with the modified oligos. Although only one of 
the monoadducts can be seen at the three hour time point, at longer 
reaction times both of these bands can be seen (data not shown). 
Also, it appears that the yield of monoadduct is lower for the 
9-mer-alt than for the other two 9-mers at the three hour time point; 
yet, by six hours no differences among the three can be detected 
(data not shown). 
PURIFICATION AND ANALYSIS OF THE 9-MER MONOADDUCT 
The monoadduct of the unmodified 9-mer was isolated and purified 
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Lane 1: 0 time. 
otoreactions with AMT. Equimolar amounts (90 
-mer and 5-mer were equilibrated with AMT 
irradiated with 400 nm radiation at 4°C. 









monoadduct with methylphosphonated 
Procedure as above in figure 7. Each 
is shown at 0, 1, and 3 hours. Lanes 1-3: 




HPLC column as described above. Chromatographic analysis of the 
peaks eluted off the column is shown is figure 9. The peaks eluting 
at 1224 s and 1362 s were characterized by recording their UV spectra 
(figures 10 and 11) using a scanning detector as they eluted from the 
HPLC column. The spectrum of the peak at 1224 s seen in figure 10 is 
characteristic of unmodified DNA and has been shown to be the 
unreacted 9-mer (Gasparro e_t. a_l., unpublished results). Figure 11 
shows the UV spectrum of the species eluting at 1362 s. The shoulder 
at 327 nm is characteristic of 4',5 ’-monoadducts. Using the 
integrated areas of these two peaks, it was calculated that 27.6% of 
the original 9-mer was converted to monoadduct. (For the several 
runs done, the yields ranged from about 20% - 30%). The fractions 
containing the monoadduct were pooled and concentrated. 
DIGESTION OF THE 9-MER MONOADDUCT 
The 9-mer monoadduct was tested for its susceptibility to T4 
polymerase. Figure 1 (lanes 13-16) reveals of the results of this 
ezymatic digestion after 0, 1 min., 10 min., and 30 min. By 30 min., 
the reaction mixture appears to contain 8-mer, 7-mer, and a small 
amount of 6-mer as well as some of the original 9-mer. Although some 
digestion has taken place, the monoadduct is far more stable than the 
unmodified 9-mer, which, as discussed above, is completely degraded 
by 10 min. (lane 6). 
FATE OF THE 9-MER MONOADDUCT IN VIVO 
The stability of the 9-mer monoadduct after incorporation into E. 
coli cells was also determined. Fractions of cells were collected at 
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RETENTION TIME (Sec.) 
HPLC analysis of 9-mer:5-mer photoreaction with AMT. A 
mobile phase consisting of acetonitrile and 0.1 M 
triethyl ammonium acetate was used with the gradient as 
described above to elute the oligonucleotides from the C8 
column. Absorbance at 260 nm is recorded. The AMT came off 
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0, 10, 20, and 30 min. during Che initial incubation of the cells 
with the 9-mer monoadduct as well as following the heat shock and the 
one hour incubation at 37°C. The results of the 20% polyacylamide 
gel are shown in figure 12. Lanes 1 and 14 correspond to the end 
labeled 9-mer monoadduct reaction mixture that has not been incubated 
with the cells. The even numbered lanes correspond to the 
supernatant from the cells after exposure to the 9-mer monoadduct at 
each of the above points during the protocol. The odd numbered lanes 
represent the cellular fractions in the same sequence. The results 
indicate that the monoadduct remains intact throughout, even after 
heat shock and one hour incubation. Although the band in lane 13, 
representing the cellular fraction following the one hour incubation, 
is quite faint, the cpm for this sample (5.18 x 10 cpm) compared 
with the total cpm added (6.89 x 10 cpm) indicates that 7.5% of 
the monoadduct was incorporated into the cells. This is in agreement 
with previous data from Gasparro et. al. In contrast, samples 
incubated with unmodified 9-mer in which the oligos undergo 
degradation after heat shock and incubation (data not shown). These 
results support the in vitro data and indicate that the presence of 
the monoadduct imparts some degree of nuclease resistance upon the 
oligonucleotide. 
PREPARATION OF A PHOSPHOROTHIOATED OLIGO MONOADDUCT 
A phosphorothioated 15-mer was also used in the photoreaction 
experiments. A reaction mixture consisting of the 15-mer:9-mer 
minihelix and 8-MOP was exposed to 400 nm radiation for 4 hours and 
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Stability of 9-mer-MA in E. coli. Lanes 1 and 14: 9-mer-MA 
marker. Lanes 2-13: even numbered lanes - supernatant from 
cells after exposure to 9-mer-MA for 0 min (lane 2), 10 min. 
(lane 9), 20 min. (lane 6), and 30 min. (lane 8) incubations 
on ice, 92°C heat shock (lane 10), and 37°C incubation (lane 
12); odd numbered lanes - cellular fractions in the same 




then applied to reversed phase HPLC. Figure 13 shows the 
chromatographic analysis of this reaction mixture. As above, the 
peaks were characterized by recording their spectra using a scanning 
detector as they eluted from the HPLC column. The spectrum of the 
first peak (figure 14) is classic for DNA. The shoulder at 330 nm in 
the spectrum of the second peak is characteristic of 4' ,5'- 
monoadducts (figure 15). The percentage of starting material 
converted into monoadduct ranged from 18-28. The fractions 
corresponding to the monoadduct were pooled and concentrated. A UV 
spectrum of the purified monoadduct is found in figure 16. Again, 















HPLC analysis of 15-mer:9-mer photoreactions. Conditions 
and gradient of this C4 column are found in the text. 
Absorbance at 260 nm is shown. Note: scaffolding 9-mer 
elutes from the column within the first 4 min. of the 




































































This study was designed to determine whether oligonucleotides 
could be modified to protect them from enzymatic degradation without 
destroying their ability to participate in photochemical reactions 
with psoralens. The particular oligonucleotides studied, a 9-mer and 
a 15-mer, were chosen because of their use in ongoing antisense 
experiments. In these investigations, the antisense oligos are 
psoralen-photomodified and directed against cellular genomic DNA. In 
the presence of UVA, the psoralen will covalently crosslink the DNA 
thereby potentially influencing gene expression. ^ 
It has been well established that unmodified oligos are very 
susceptible to degradation by enzymes found in the cytoplasm of 
cells. This has been confirmed in the present study. Unmodified 
oligonucleotides were shown to be susceptible to degradation by a 
5'-exonuclease (phosphodiesterase II), a 3 ’-exonuclease (T4 
polymerase), and acid phosphatase. They were also digested rapidly 
when introduced into an in vivo system (E. coin). 
As discussed above, several groups have modified the 
sugar-phosphodiester backbone with methylphosphonate linkages in 
3 5 36 
order to retard digestion by enzymes. ’ Although this 
modification has successfully increased the stability of the oligos, 
it has produced several disadvantages. These modified oligos have 
q / 
low solubility in aqueous media, involve a synthesis that is not 
stereospecific thereby increasing the number of stereoisomers 
produced, and when directed against mRNA do not cause RNase catalyzed 
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cleavage of the target. One way to limit these drawbacks is to 
modify only a subset of the bases of a particular oligo. Tidd and 
O £ 
Warenius employed this strategy of partial modification in order 
to isolate the relative contributions to the degradation of 
oligonucleotides of several enzymes in fetal calf serum. They 
modified the 3'-end, the 5'-end, or both and concluded that blockage 
of the 3'-end was sufficient to enhance the lifetime of the oligo in 
the presence of fetal calf serum. 
In this present work, three different methylphosphonated oligos, 
each nine bases long, were used: one with methylphosphonates on the 
three middle bases (9-mer-TAT), one with methylphosphonates on every 
other base (9-mer-alt), and one with methylphosphonates on the 
second, third, eighth, and ninth bases (9-mer-AG) (see table 1). 
When reacted with the 5'-exonuclease, it was the 9-mer-AG that was 
most resistant to degradation. This oligo is the only one of the 
three that has two methylphosphonate groups next to each other close 
to the 5'-terminus. 
Similarly, the 9-mer-AG is also most resistant to the 
3'-exonuclease. Surprising, however, is the result that 9-mer-TAT, 
which only has methylphosphonates on the three middle bases, is also 
quite resistant to this enzyme. One might have expected that the 
first three unmodified bases of 9-mer-TAT would be cleaved by the 
exonuclease. This may suggest that the methylphosphonates in the 
middle alter the conformation of the oligo, thereby decreasing the 
likelihood of contact with the enzyme or the binding affinity. The 
results of the experiments with acid phosphatase support this 
hypothesis. 9-mer-TAT is the only one of the three oligos in which 
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any of the starting material remains after the 30 min. digestion. 
Since the 5'-terminus is unmodified in all three oligos, there must 
be another factor allowing 9-mer-TAT to be more resistant. A 
conformational change could explain this difference. 
In addition, 9-mer-MA also conferred increased stability to the 
oligo. This was seen both in the in vitro and the in vivo settings. 
The in vivo data shows that the 9-mer-MA introduced into E. coli 
persists even after one hour incubation at 37°C. As in the above 
example, this oligo has unmodified ends potentially at risk for 
degradation. Yet, the psoralen attached in the middle of the piece 
of DMA makes it less susceptible to degradation as compared to the 
unmodified oligonucleotide. Several explanations are possible to 
account for this result. It is possible that the enzyme is blocked 
by steric hinderance - that is that the somewhat "bulky" psoralen 
physically impedes the contact of the enzyme with the oligo. The 
above hypothesis of a conformational change is also conceivable. 
These findings demonstrate an increased utility for the 
psoralen-modified oligos. The monoadduct in the presence of UVA 
forms a covalent crosslink with the target DNA thereby increasing the 
length of time the target is inactivated. In addition, it now 
appears that the psoralen also allows more oligos to reach their 
targets intact. 
One concern of using modified oligonucleotides, either 
methylphosphonates or phosphorothioates, is that these changes in the 
backbone would interfere with the photochemistry necessary to create 
the psoralen monoadducts. The photochemical experiments done, 
however, demonstrate that both methylphosphonates and 
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photomodified with psoralen with phosphorothioates can be 
approximately the same yields as with unmodified 9-mer. Even the 
9-mer-TAT and the 9-mer-alt, in which the particular thymidine that 
is photomodified has the methylphosphonate substitution, are able to 
react with psoralen. 
As Gasparro et_. al. ^ have stressed, this method of 
photomodification offers several advantages over other strategies 
used to attach psoralens to oligos. Other groups^ ’5 ’55 (see 
above) have employed a tether to link the psoralen to the oligo. The 
strategy used by Gasparro et. al. and used in this paper is 
relatively straightforward, involving a four hour irradiation and 
HPLC purification. Second, in order to attach the tether to the 
oligo, the above groups have had to use the 4' position in the furan 
ring. These papers have noted that use of this sight has disrupted 
effective photochemical reactions and led to increased 
photodegradation of the product. 
Thus, these experiments have shown several ways to improve upon 
the antisense technology. Several additional studies are being 
planned to further characterize the phosphorothioates and the 
monoadducts. The in vivo study should be repeated in a eukaryotic 
system. Previous work (see above) has shown that phosphorothioates 
preferentially target the nucleus. Experiments to localize 
phosphorothioate monoadducts should also be performed. 
The problem of stability of the oligonucleotides is of great 
concern when trying to apply this technology to the clinical 
setting. The ability to control gene expression at the level of the 
DNA has great therapeutic potential; however, in order for the 
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oligonucleotide to reach the DNA it must cross two hostile 
compartments- the cytoplasm and the nucleus. It is imperative, 
therefore, that the oligonucleotides are protected, but protected 
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